Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2024 | 395 | 2.870 |
Why?
|
| Insurance Claim Review | 2 | 2023 | 45 | 1.120 |
Why?
|
| Leukemia, Myeloid, Acute | 8 | 2024 | 788 | 1.120 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 54 | 1.050 |
Why?
|
| Cancer Survivors | 2 | 2022 | 95 | 0.870 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2023 | 37 | 0.860 |
Why?
|
| Lymphoma, T-Cell | 1 | 2023 | 55 | 0.860 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 48 | 0.860 |
Why?
|
| Lymphoma | 1 | 2023 | 265 | 0.790 |
Why?
|
| Psychotherapy, Brief | 1 | 2021 | 12 | 0.780 |
Why?
|
| Neoplasms | 4 | 2024 | 3035 | 0.690 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2024 | 889 | 0.530 |
Why?
|
| Adolescent | 7 | 2024 | 9237 | 0.410 |
Why?
|
| Health Care Costs | 2 | 2023 | 235 | 0.390 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2024 | 412 | 0.380 |
Why?
|
| Humans | 24 | 2024 | 89073 | 0.300 |
Why?
|
| United States | 4 | 2024 | 6957 | 0.290 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2024 | 88 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 2552 | 0.270 |
Why?
|
| Adult | 10 | 2024 | 26508 | 0.260 |
Why?
|
| Retrospective Studies | 6 | 2024 | 9003 | 0.250 |
Why?
|
| Sulfonamides | 2 | 2024 | 317 | 0.240 |
Why?
|
| CD47 Antigen | 1 | 2024 | 23 | 0.230 |
Why?
|
| Aniline Compounds | 1 | 2023 | 58 | 0.220 |
Why?
|
| Aminopyridines | 1 | 2023 | 40 | 0.220 |
Why?
|
| Triazines | 1 | 2023 | 53 | 0.220 |
Why?
|
| Pyrazines | 1 | 2023 | 94 | 0.220 |
Why?
|
| Survivors | 2 | 2022 | 233 | 0.220 |
Why?
|
| Mental Health | 1 | 2024 | 176 | 0.210 |
Why?
|
| Costs and Cost Analysis | 1 | 2023 | 153 | 0.210 |
Why?
|
| Blood Platelet Disorders | 1 | 2022 | 9 | 0.210 |
Why?
|
| Health Resources | 1 | 2023 | 81 | 0.210 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2022 | 22 | 0.200 |
Why?
|
| Young Adult | 6 | 2024 | 6289 | 0.200 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 106 | 0.200 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 582 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 257 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 360 | 0.180 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 342 | 0.180 |
Why?
|
| Acute Disease | 1 | 2022 | 841 | 0.180 |
Why?
|
| Self Report | 1 | 2021 | 295 | 0.170 |
Why?
|
| Female | 9 | 2024 | 46014 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2021 | 865 | 0.160 |
Why?
|
| Mutation | 3 | 2024 | 4132 | 0.160 |
Why?
|
| Hyperbilirubinemia | 1 | 2018 | 21 | 0.160 |
Why?
|
| Carnitine | 1 | 2018 | 14 | 0.150 |
Why?
|
| Asparaginase | 1 | 2018 | 35 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 410 | 0.150 |
Why?
|
| Hospitalization | 1 | 2023 | 876 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2023 | 669 | 0.150 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 66 | 0.150 |
Why?
|
| Male | 7 | 2024 | 42254 | 0.150 |
Why?
|
| Depression | 1 | 2021 | 503 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 1223 | 0.140 |
Why?
|
| Quality of Life | 1 | 2024 | 1662 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 358 | 0.130 |
Why?
|
| Philadelphia Chromosome | 2 | 2024 | 41 | 0.110 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2023 | 131 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 2412 | 0.100 |
Why?
|
| Transplantation, Homologous | 2 | 2024 | 996 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2024 | 616 | 0.090 |
Why?
|
| Aged | 5 | 2024 | 19078 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 604 | 0.090 |
Why?
|
| Middle Aged | 5 | 2024 | 25865 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1363 | 0.070 |
Why?
|
| Amenorrhea | 1 | 2024 | 28 | 0.060 |
Why?
|
| Menstruation | 1 | 2024 | 35 | 0.060 |
Why?
|
| Premenopause | 1 | 2024 | 57 | 0.060 |
Why?
|
| Menorrhagia | 1 | 2024 | 26 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2024 | 108 | 0.060 |
Why?
|
| Tranexamic Acid | 1 | 2024 | 37 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2023 | 54 | 0.060 |
Why?
|
| Allografts | 1 | 2024 | 181 | 0.060 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 37 | 0.060 |
Why?
|
| Induction Chemotherapy | 1 | 2024 | 151 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 6777 | 0.060 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 95 | 0.050 |
Why?
|
| Retreatment | 1 | 2022 | 108 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 57 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 196 | 0.050 |
Why?
|
| Myeloproliferative Disorders | 1 | 2024 | 132 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 235 | 0.050 |
Why?
|
| Germ Cells | 1 | 2022 | 130 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2024 | 357 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2022 | 291 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2023 | 374 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 645 | 0.050 |
Why?
|
| Survival Rate | 1 | 2024 | 1889 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2024 | 8203 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2018 | 92 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 2553 | 0.040 |
Why?
|
| Apoptosis | 1 | 2023 | 1717 | 0.030 |
Why?
|
| Prognosis | 1 | 2024 | 3773 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 967 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 740 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2018 | 711 | 0.030 |
Why?
|
| Liver | 1 | 2018 | 1205 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2023 | 3374 | 0.030 |
Why?
|
| Child | 1 | 2018 | 7149 | 0.020 |
Why?
|